338 related articles for article (PubMed ID: 17976674)
21. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions.
Stiborová M; Moserová M; Černá V; Indra R; Dračínský M; Šulc M; Henderson CJ; Wolf CR; Schmeiser HH; Phillips DH; Frei E; Arlt VM
Toxicology; 2014 Apr; 318():1-12. PubMed ID: 24530354
[TBL] [Abstract][Full Text] [Related]
22. Activation and detoxification metabolism of urban air pollutants 2-nitrobenzanthrone and carcinogenic 3-nitrobenzanthrone by rat and mouse hepatic microsomes.
Stiborova M; Cechova T; Borek-Dohalska L; Moserova M; Frei E; Schmeiser HH; Paca J; Arlt VM
Neuro Endocrinol Lett; 2012; 33 Suppl 3():8-15. PubMed ID: 23353838
[TBL] [Abstract][Full Text] [Related]
23. Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice.
Arlt VM; Singh R; Stiborová M; Gamboa da Costa G; Frei E; Evans JD; Farmer PB; Wolf CR; Henderson CJ; Phillips DH
Drug Metab Dispos; 2011 Dec; 39(12):2169-73. PubMed ID: 21940903
[TBL] [Abstract][Full Text] [Related]
24. Chlorzoxazone hydroxylation in microsomes and hepatocytes from cytochrome P450 oxidoreductase-null mice.
Li L; Porter TD
J Biochem Mol Toxicol; 2009; 23(5):357-63. PubMed ID: 19827131
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells.
Martinkova E; Dontenwill M; Frei E; Stiborova M
Neuro Endocrinol Lett; 2009; 30 Suppl 1():60-6. PubMed ID: 20027146
[TBL] [Abstract][Full Text] [Related]
26. The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide.
Stiborová M; Sejbal J; Borek-Dohalská L; Aimová D; Poljaková J; Forsterová K; Rupertová M; Wiesner J; Hudecek J; Wiessler M; Frei E
Cancer Res; 2004 Nov; 64(22):8374-80. PubMed ID: 15548707
[TBL] [Abstract][Full Text] [Related]
27. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
Stiborová M; Bieler CA; Wiessler M; Frei E
Biochem Pharmacol; 2001 Dec; 62(12):1675-84. PubMed ID: 11755121
[TBL] [Abstract][Full Text] [Related]
28. The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: studies with rats, Hepatic Cytochrome P450 Reductase Null (HRN™) mice and pure enzymes.
Stiborová M; Černá V; Moserová M; Mrízová I; Arlt VM; Frei E
Int J Mol Sci; 2014 Dec; 16(1):284-306. PubMed ID: 25547492
[TBL] [Abstract][Full Text] [Related]
29. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
30. Protection against Trp-P-2 DNA adduct formation in C57bl6 mice by purpurin is accompanied by induction of cytochrome P450.
Marczylo T; Sugiyama C; Hayatsu H
J Agric Food Chem; 2003 May; 51(11):3334-7. PubMed ID: 12744663
[TBL] [Abstract][Full Text] [Related]
31. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
32. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Stiborová M; Frei E; Hodek P; Wiessler M; Schmeiser HH
Int J Cancer; 2005 Jan; 113(2):189-97. PubMed ID: 15386410
[TBL] [Abstract][Full Text] [Related]
33. Deletion of cytochrome P450 oxidoreductase enhances metabolism and DNA adduct formation of benzo[a]pyrene in Hepa1c1c7 cells.
Reed L; Jarvis IWH; Phillips DH; Arlt VM
Mutagenesis; 2019 Dec; 34(5-6):413-420. PubMed ID: 31612222
[TBL] [Abstract][Full Text] [Related]
34. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
35. Bromopropylate: induction of hepatic cytochromes P450 and absence of covalent binding to DNA in mouse liver.
Thomas H; Sagelsdorff P; Molitor E; Skripsky T; Waechter F
Toxicol Appl Pharmacol; 1994 Nov; 129(1):155-62. PubMed ID: 7974489
[TBL] [Abstract][Full Text] [Related]
36. Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases.
Arlt VM; Henderson CJ; Wolf CR; Schmeiser HH; Phillips DH; Stiborova M
Cancer Lett; 2006 Mar; 234(2):220-31. PubMed ID: 15885895
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine.
Sulc M; Mrizova I; Cerna T; Frei E; Eckschlager T; Adam V; Kopeckova K; Stiborova M
Neuro Endocrinol Lett; 2016 Dec; 37(Suppl1):95-102. PubMed ID: 28263536
[TBL] [Abstract][Full Text] [Related]
38. Polycyclic aromatic hydrocarbon-inducible DNA adducts: evidence by 32P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo.
Kondraganti SR; Fernandez-Salguero P; Gonzalez FJ; Ramos KS; Jiang W; Moorthy B
Int J Cancer; 2003 Jan; 103(1):5-11. PubMed ID: 12455047
[TBL] [Abstract][Full Text] [Related]
39. Assessment of the hepatic CYP reductase null mouse model and its potential application in drug discovery.
Boggs JW; Hop CE; McNamara E; Deng Y; Messick K; West K; Choo EF
Mol Pharm; 2014 Mar; 11(3):1062-8. PubMed ID: 24450768
[TBL] [Abstract][Full Text] [Related]
40. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.
Frei E; Bieler CA; Arlt VM; Wiessler M; Stiborová M
Biochem Pharmacol; 2002 Jul; 64(2):289-95. PubMed ID: 12123750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
